AUTOLUS LTD has a total of 360 patent applications. It increased the IP activity by 96.0%. Its first patent ever was published in 2014. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are NANJING IASO BIOTHERAPEUTICS CO LTD, CERO THERAPEUTICS INC and IMMVIRA CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 102 | |
#2 | WIPO (World Intellectual Property Organization) | 61 | |
#3 | Australia | 39 | |
#4 | EPO (European Patent Office) | 39 | |
#5 | United States | 38 | |
#6 | Canada | 23 | |
#7 | China | 21 | |
#8 | Israel | 8 | |
#9 | Chile | 6 | |
#10 | Brazil | 5 | |
#11 | Hong Kong | 4 | |
#12 | Republic of Korea | 4 | |
#13 | Singapore | 3 | |
#14 | Mexico | 2 | |
#15 | Colombia | 1 | |
#16 | Cuba | 1 | |
#17 | Japan | 1 | |
#18 | Peru | 1 | |
#19 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Organic fine chemistry | |
#6 | Environmental technology | |
#7 | Agriculture |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Analysing materials | |
#6 | Enzymes | |
#7 | Measuring microorganism processes | |
#8 | Combinatorial chemistry | |
#9 | Animal care | |
#10 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Cordoba Shaun | 167 |
#2 | Thomas Simon | 144 |
#3 | Pulé Martin | 136 |
#4 | Onuoha Shimobi | 123 |
#5 | Pule Martin | 64 |
#6 | Sillibourne James | 41 |
#7 | Righi Matteo | 40 |
#8 | Kokalaki Evangelia | 34 |
#9 | Ferrari Mathieu | 31 |
#10 | Jha Ram | 22 |
Publication | Filing date | Title |
---|---|---|
GB202103101D0 | Generation of T-cells by direct reprogramming from fibroblasts and MSC | |
GB202103001D0 | Polypeptide | |
GB202101491D0 | Molecule | |
GB202100688D0 | Process | |
GB202017649D0 | Polypeptide | |
GB202017358D0 | Cell | |
GB202017343D0 | Cell | |
GB202013372D0 | Polypeptide | |
GB202012181D0 | Chimeric receptor | |
WO2021009510A1 | Method for preconditioning a subject who is about to receive a t-cell therapy | |
GB202005331D0 | Cell | |
GB202005333D0 | Polypeptide | |
GB202005216D0 | Cell | |
GB202005184D0 | Method | |
GB202004263D0 | Antibody conjugate | |
WO2020183131A1 | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car | |
GB201919017D0 | Cell | |
GB201919019D0 | Antigen-binding domain | |
GB201918906D0 | Cell | |
GB201918908D0 | Cell |